Krebs Biochemicals & Industries Ltd Hits 52-Week Low Amidst Continued Downtrend

Stock Price Movement and Market Context

The stock of Krebs Biochemicals & Industries Ltd, operating in the Pharmaceuticals & Biotechnology sector, recorded an intraday low of Rs.60.17 on 20 Jan 2026, representing a 2.95% decrease on the day. Despite opening with a positive gap of 3.31% at Rs.64.05, the stock reversed course to close near its lowest point. This decline comes after two consecutive days of losses, during which the stock has fallen by 8.07%. Notably, the stock has underperformed its sector by 1.16% today and has traded erratically, missing trading activity on one day in the last 20 sessions.

Technical indicators show Krebs Biochemicals trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling sustained downward momentum. The stock’s 52-week high stands at Rs.113.90, highlighting the extent of the recent depreciation.

Broader Market Environment

The decline in Krebs Biochemicals’ share price coincides with a weakening broader market. The Sensex opened flat but subsequently fell sharply by 849.68 points, or 1.07%, closing at 82,357.70. This marks the third consecutive weekly decline for the index, which has lost 3.97% over the past three weeks. The Sensex remains 4.62% below its 52-week high of 86,159.02 and is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, indicating some underlying market resilience.

Financial Performance and Fundamental Assessment

Krebs Biochemicals & Industries Ltd’s financial metrics reflect ongoing difficulties. The company has reported negative results for four consecutive quarters, with a net loss after tax (PAT) of Rs. -19.73 crores over the latest nine months, representing a decline of 58.24% compared to previous periods. Net sales for the latest six months stand at Rs.9.65 crores, down 62.52% year-on-year, indicating a significant contraction in revenue generation.

The company’s long-term growth trajectory has been weak, with net sales declining at an annual rate of 11.65% over the past five years and operating profit remaining flat. The average debt-to-equity ratio is reported at zero, but the company carries a negative book value, signalling weak long-term fundamental strength. Additionally, the debtors turnover ratio for the half-year is at a low 19.44 times, suggesting challenges in receivables management.

Valuation and Risk Profile

The stock’s valuation metrics indicate elevated risk. It is trading below all major moving averages and has generated a negative return of 36.01% over the past year, compared to a positive 6.86% return by the Sensex. Profitability has also deteriorated, with profits falling by 26.2% over the same period. The company’s EBITDA remains negative, further underscoring the financial strain.

Over the last three years, Krebs Biochemicals has underperformed the BSE500 index across multiple time frames, including the last three months, one year, and three years, reflecting persistent challenges in both near-term and long-term performance.

Shareholding and Market Capitalisation

The majority shareholding in Krebs Biochemicals & Industries Ltd remains with the promoters, maintaining control over corporate decisions. The company holds a Market Cap Grade of 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector. The Mojo Score currently stands at 3.0, with a Mojo Grade of Strong Sell, upgraded from Sell on 6 Feb 2025, indicating a deteriorated outlook based on MarketsMOJO’s comprehensive evaluation.

Summary of Key Metrics

To summarise, Krebs Biochemicals & Industries Ltd’s stock has reached a new 52-week low of Rs.60.17, amid a broader market downturn and company-specific financial pressures. The stock’s recent performance includes:

• Two consecutive days of losses, totalling an 8.07% decline
• Trading below all major moving averages
• Negative PAT of Rs. -19.73 crores over nine months, down 58.24%
• Net sales down 62.52% in the latest six months to Rs.9.65 crores
• Negative EBITDA and weak long-term growth trends
• Underperformance relative to Sensex and BSE500 indices

These factors collectively contribute to the stock’s current valuation and risk profile within the Pharmaceuticals & Biotechnology sector.

Market and Sector Comparison

While Krebs Biochemicals has struggled, the broader Pharmaceuticals & Biotechnology sector has shown mixed performance. The stock’s underperformance relative to its sector by 1.16% today and its sustained decline over recent periods highlight company-specific issues beyond general market trends. The Sensex’s recent volatility and three-week consecutive fall have also contributed to a challenging environment for stocks across sectors.

Technical Indicators and Trading Patterns

The stock’s failure to sustain gains despite an initial gap-up opening today suggests selling pressure at higher levels. The intraday high of Rs.64.05 was not maintained, with the price retreating to the day’s low. The absence of trading on one day in the last 20 sessions adds to the erratic trading pattern, which may reflect liquidity constraints or investor caution.

Conclusion

Krebs Biochemicals & Industries Ltd’s fall to a 52-week low of Rs.60.17 reflects a combination of weak financial results, negative profitability trends, and broader market headwinds. The stock’s technical and fundamental indicators point to a challenging phase, with sustained underperformance relative to benchmarks and sector peers. The company’s negative book value and declining sales further compound the cautious outlook reflected in its Strong Sell Mojo Grade.

Unlock special upgrade rates for a limited period. Start Saving Now →